Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
R256918 · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | R256918 10 mg capsule twice daily |
| 002 | EXPERIMENTAL | R256918 15 mg capsule twice daily |
| 003 | PLACEBO_COMPARATOR | placebo placebo capsule twice daily |
| 004 | PLACEBO_COMPARATOR | placebo Placebo capsule twice daily |
| Name | Type | Description |
|---|---|---|
| R256918 | DRUG | 10 mg capsule twice daily |
| placebo | DRUG | placebo capsule twice daily |
Inclusion Criteria: * Liver fat content (HTGC) between 3% and 15% * Obese defined as BMI between 30 and 50 kg/square meter * Fasting plasma glucose \< 7.0 mmol/liter Exclusion Criteria: * History of Obesity with a known cause (eg. Cushings disease) * Diabetes Mellitus * Weight reducing diet or re...
Top 20 of 32 competitors
R256918 is an investigational small molecule being developed for obesity. It is being studied in overweight and obese patients as part of a clinical development program. The drug is not approved and remains in clinical trials.
R256918 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The company is conducting clinical trials to evaluate the drug's safety and effectiveness in patients with obesity.
R256918 is in Phase 2 clinical development. Two Phase 2 trials have been completed, with a total of 392 participants enrolled. The drug is investigational and has not been approved by regulatory authorities.
R256918 has been studied in two completed Phase 2 trials. NCT00622765 enrolled 321 overweight and obese patients across seven European countries, and NCT01041677 enrolled 71 obese patients in Finland, the Netherlands, and Sweden. Both trials were randomized, double-blind, and placebo-controlled.
Yes, R256918 is also known as JNJ-16269110. The first clinical trial, NCT00622765, used the name JNJ-16269110 in its title, while the second trial, NCT01041677, used R256918. Both names refer to the same investigational drug for obesity.